call Toll Free (US/Canada) : +1 866 658 6826 | call +1 425 320 4776 | call (UK) : +44 1865 60 0662 | email info(@)blueweaveconsulting.com
Home | About Us | Career | Services | Blog | Contact Us
Home Blog Takeda Pharmaceutical Company Limited gets shareholder approval to acquire Shire for USD 46 billion

Takeda Pharmaceutical Company Limited gets shareholder approval to acquire Shire for USD 46 billion

  • Published | 06 December 2018

Japanese pharmaceutical company Takeda pharmaceutical will be acquiring UK based pharmaceutical company Shire after the approval of its shareholders

India: Takeda Pharmaceutical shareholders has approval to finance its USD 52.21 billion purchase of Shire, paving the way for Japan largest corporate takeover and the creation of a global drug maker. The Japanese market represents 7% of the global market. Company has taken the strategic decision to expand their global footprint, and strengthen their market position outside Japan.  The acquisition is estimated to close by January 8, will add Shire’s lucrative rare diseases portfolio to Takeda’s product pipeline, which lacked big late-development experimental drugs. It will also increase the company’s exposure in the US, the world’s largest pharmaceutical market, which will account for roughly half of its revenue after integrating Shire. According to BlueWeave Consulting, The global pharmaceuticals market was over USD 907.3 billion in 2017 and anticipated to reach USD 1020 billion in 2021, growing at 5.54%. The factors affecting the pharmaceutical market comprises of drug affordability, supportive government policies, disease prevalence and consumer attitudes to health and hygiene. According to the upcoming report by BlueWeave Consulting on “Global Pharmaceutical Excipients Market, By Functionality, By Formulation, By Region- Industry Analysis, Size, Share, Growth, Trends & forecast by 2018-2025”, rapidly growing pharmaceutical industry is promulgating the advance functional excipients market. Key factors such as the development of multifunctional & co-processed excipients, shifting focus of pharmaceutical manufacturers to emerging markets, increasing biologics and biosimilars industry are driving the market over the forecast period.